Steffen Marquardt1, Martha M Kirstein2, Roland Brüning3, Martin Zeile3, Pier Francesco Ferrucci4, Warner Prevoo5, Boris Radeleff6, Hervé Trillaud7, Lambros Tselikas8, Emilio Vicente9, Philipp Wiggermann10, Michael P Manns2, Arndt Vogel2, Frank K Wacker11. 1. Department of Diagnostic and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. 2. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 3. Department of Radiology and Neuroradiology, Asklepios Klinik Barmbek, Hamburg, Germany. 4. Melanoma Medical Treatment Unit, European Institute of Oncology, Milan, Italy. 5. Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany. 7. Department of Radiology, Bordeaux University Hospital Center, Bordeaux, France. 8. Department of Radiology, Gustave Roussy Cancer Campus, Paris, France. 9. General Surgery Department, HM University Sanchinarro Hospital, Madrid, Spain. 10. Department of Radiology, University Hospital Regensburg, Regensburg, Germany. 11. Department of Diagnostic and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. wacker.frank@mh-hannover.de.
Abstract
OBJECTIVES: Cholangiocarcinoma is the second most common primary liver tumour with a poor overall prognosis. Percutaneous hepatic perfusion (PHP) is a directed therapy for primary and secondary liver malignancies, and its efficacy and safety have been shown in different entities. The purpose of this study was to prove the safety and efficacy of PHP in patients with unresectable intrahepatic cholangiocarcinoma (iCCA). PATIENTS AND METHODS: We retrospectively reviewed data from 15 patients with unresectable iCCA treated with PHP in nine different hospitals throughout Europe. Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumours (RECIST1.1). Overall survival (OS), progression-free survival (PFS) and hepatic PFS (hPFS) were analysed using the Kaplan-Meier estimation. Adverse events (AEs) and toxicity were evaluated. RESULTS: Fifteen patients were treated with 26 PHPs. ORR was 20%, disease control was achieved in 53% after the first PHP. Median OS was 26.9 months from initial diagnosis and 7.6 months from first PHP. Median PFS and hPFS were 122 and 131 days, respectively. Patients with liver-only disease had a significantly longer median OS compared to patients with locoregional lymph node metastases (12.9 vs. 4.8 months, respectively; p < 0.01). Haematological toxicity was common, but manageable. No AEs of grade 3 or 4 occurred during the procedures. DISCUSSION: PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with iCCA, especially in non-metastatic disease. KEY POINTS: • Percutaneous hepatic perfusion (PHP) offers an additional locoregional therapy strategy for the treatment of unresectable primary or secondary intrahepatic malignancies. • PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with intrahepatic cholangiocarcinoma (iCCA), especially in non-metastatic disease. • Side effects seem to be tolerable and comparable to other systemic or local treatment strategies.
OBJECTIVES:Cholangiocarcinoma is the second most common primary liver tumour with a poor overall prognosis. Percutaneous hepatic perfusion (PHP) is a directed therapy for primary and secondary liver malignancies, and its efficacy and safety have been shown in different entities. The purpose of this study was to prove the safety and efficacy of PHP in patients with unresectable intrahepatic cholangiocarcinoma (iCCA). PATIENTS AND METHODS: We retrospectively reviewed data from 15 patients with unresectable iCCA treated with PHP in nine different hospitals throughout Europe. Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumours (RECIST1.1). Overall survival (OS), progression-free survival (PFS) and hepatic PFS (hPFS) were analysed using the Kaplan-Meier estimation. Adverse events (AEs) and toxicity were evaluated. RESULTS: Fifteen patients were treated with 26 PHPs. ORR was 20%, disease control was achieved in 53% after the first PHP. Median OS was 26.9 months from initial diagnosis and 7.6 months from first PHP. Median PFS and hPFS were 122 and 131 days, respectively. Patients with liver-only disease had a significantly longer median OS compared to patients with locoregional lymph node metastases (12.9 vs. 4.8 months, respectively; p < 0.01). Haematological toxicity was common, but manageable. No AEs of grade 3 or 4 occurred during the procedures. DISCUSSION: PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with iCCA, especially in non-metastatic disease. KEY POINTS: • Percutaneous hepatic perfusion (PHP) offers an additional locoregional therapy strategy for the treatment of unresectable primary or secondary intrahepatic malignancies. • PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with intrahepatic cholangiocarcinoma (iCCA), especially in non-metastatic disease. • Side effects seem to be tolerable and comparable to other systemic or local treatment strategies.
Authors: Martha M Kirstein; Steffen Marquardt; Nils Jedicke; Silke Marhenke; Wolfgang Koppert; Michael P Manns; Frank Wacker; Arndt Vogel Journal: J Cancer Res Clin Oncol Date: 2017-06-20 Impact factor: 4.553
Authors: Thomas J Vogl; Nagy N N Naguib; Nour-Eldin A Nour-Eldin; Wolf O Bechstein; Stefan Zeuzem; Jörg Trojan; Tatjana Gruber-Rouh Journal: Int J Cancer Date: 2011-10-05 Impact factor: 7.396
Authors: Andrea M Abbott; Matthew P Doepker; Youngchul Kim; Matthew C Perez; Cassandra Gandle; Kerry L Thomas; Junsung Choi; Ravi Shridhar; Jonathan S Zager Journal: Am J Clin Oncol Date: 2018-08 Impact factor: 2.339
Authors: Charles E Ray; Anthony Edwards; Mitchell T Smith; Stephen Leong; Kimi Kondo; Matthew Gipson; Paul J Rochon; Rajan Gupta; Wells Messersmith; Tom Purcell; Janette Durham Journal: J Vasc Interv Radiol Date: 2013-05-28 Impact factor: 3.464
Authors: Meghan R Forster; Omar M Rashid; Matthew C Perez; Junsung Choi; Tariq Chaudhry; Jonathan S Zager Journal: J Surg Oncol Date: 2013-11-19 Impact factor: 3.454
Authors: Fred M Moeslein; Elizabeth G McAndrew; William M Appling; Nicole E Hryniewich; Kevin D Jarvis; Steven M Markos; Timothy P Sheets; Rajneesh P Uzgare; Daniel S Johnston Journal: Cardiovasc Intervent Radiol Date: 2014-01-09 Impact factor: 2.740
Authors: C L A Dewald; L S Becker; S K Maschke; T C Meine; T A Alten; M M Kirstein; A Vogel; F K Wacker; B C Meyer; J B Hinrichs Journal: Clin Exp Metastasis Date: 2020-10-09 Impact factor: 5.150
Authors: T Susanna Meijer; Jan H N Dieters; Eleonora M de Leede; Lioe-Fee de Geus-Oei; Jaap Vuijk; Christian H Martini; Arian R van Erkel; Jacob Lutjeboer; Rutger W van der Meer; Fred G J Tijl; Ellen Kapiteijn; Alexander L Vahrmeijer; Mark C Burgmans Journal: PLoS One Date: 2022-01-13 Impact factor: 3.240
Authors: Sebastian Ebel; Martin Reinhardt; Anne Bettina Beeskow; Felix Teske; Manuel Florian Struck; Rhea Veelken; Florian van Boemmel; Thomas Berg; Michael Moche; Matthias Gutberlet; Holger Gößmann; Timm Denecke Journal: BMC Med Imaging Date: 2022-09-13 Impact factor: 2.795